Parkworth Wealth Management’s Revolution Medicines RVMD Stock Holding History

Parkworth Wealth Management’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$294	Buy	+8	New	+$307	﹤0.01%	803

Other funds holding RVMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Parkworth Wealth Management's RVMD Position: Q2 2025 in Review

Parkworth Wealth Management opened a new position in Revolution Medicines (RVMD) in Q2 2025: 8 shares worth $294. The stake represents ﹤0.01% of the portfolio and ranks #803 among its holdings.

308 funds tracked by Wall St. Rank hold RVMD as of Q2 2025.

Parkworth Wealth Management held 8 shares of Revolution Medicines worth $294 as of Q2 2025.
Revolution Medicines was a new Parkworth Wealth Management position in Q2 2025.
Revolution Medicines made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #803 holding.
308 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.